Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences

Abbott Laboratories (NYSE:ABT) is one of the Best Conservative Stocks to Buy Right Now. On March 23, the company announced that it had completed the acquisition of Exact Sciences. As a result of this, Abbott Laboratories (NYSE:ABT) is now a leader in fast-growing cancer screening as well as the diagnostics segment.

Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences

This acquisition places Abbott Laboratories (NYSE:ABT) well to advance diagnostics, which are more preventative, predictive, and personalized. Apart from this, it added a new growth vertical to Abbott Laboratories (NYSE:ABT)’s already high-single-digit growth outlook, which will help establish leadership in the expanding $60 billion US market focused on cancer screening and precision oncology diagnostics.

Abbott Laboratories (NYSE:ABT)’s global scale, history of achieving operational and commercial excellence, and its work with healthcare systems should help in expanding accessibility to tools for early cancer detection and personalized treatments. After the completion of the acquisition, Exact Sciences is now a wholly-owned subsidiary of Abbott Laboratories (NYSE:ABT).

Abbott Laboratories (NYSE:ABT) is a global healthcare company that manufactures a range of branded generic medications, medical devices, diagnostics, and nutritional items.

While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.